High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia

Blood

Volumn 127, Issue 12, 2016, Pages 1587-1597

  Hou, Yu ^a   Feng, Qi ^a   Xu, Miao ^a   Li, Guo Sheng ^a   Liu, Xue Na ^a   Sheng, Zi ^a   Zhou, Hai ^a   Ma, Ji ^b   Wei, Yu ^a   Sun, Yuan Xin ^a   Yu, Ying Yi ^a   Qiu, Ji Hua ^a   Shao, Lin Lin ^a   Liu, Xin Guang ^a   Hou, Ming ^a,c   Peng, Jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; CD4 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 10; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ETS 1; TRANSFORMING GROWTH FACTOR BETA; ANTIINFLAMMATORY AGENT; CYTOKINE; ETS1 PROTEIN, HUMAN; ETS1 PROTEIN, MOUSE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL POPULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE THROMBOCYTOPENIA; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECIPIENT; SPLEEN; SPLEEN CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UPREGULATION; ADAPTIVE IMMUNITY; ADOLESCENT; ANIMAL; C57BL MOUSE; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SCID MOUSE; YOUNG ADULT;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DEXAMETHASONE; FEMALE; HUMANS; MALE; MICE, INBRED C57BL; MICE, SCID; MIDDLE AGED; MYELOID CELLS; PROTO-ONCOGENE PROTEIN C-ETS-1; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; YOUNG ADULT;

EID: 84962310644     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-674531     Document Type: Article

References (54)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.
2. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499-4506.
3. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116(10):2777-2790.
4. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7): 828-835.
5. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003;24(6):302-306.
6. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005; 202(7):931-939.
7. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5(8):641-654.
8. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4): 1568-1573.
9. Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 2010;116(25):5738-5747.
10. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote crosstolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13): 5439-5449.
11. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colonystimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25(18):2546-2553.
12. Chalmin F, Ladoire S, Mignot G, et al. Membraneassociated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120(2): 457-471.
13. Cripps JG, Gorham JD. MDSC in autoimmunity. Int Immunopharmacol. 2011;11(7):789-793.
14. Slaney CY, Toker A, La Flamme A, Bäckström BT, Harper JL. Naïve blood monocytes suppress T-cell function. A possible mechanism for protection from autoimmunity. Immunol Cell Biol. 2011;89(1):7-13.
15. Raveney BJ, Copland DA, Dick AD, Nicholson LB. TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis. J Immunol. 2009;183(4): 2321-2329.
16. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood. 1991; 78(10):2619-2625.
17. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998; 102(7):1393-1402.
18. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11): 2386-2393.
19. Audia S, Samson M, Mahévas M, et al. Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood. 2013;122(14): 2477-2486.
20. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994; 330(22):1560-1564.
21. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349(9):831-836.
22. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol. 2007;79(4): 310-316.
23. Varga G, Ehrchen J, Tsianakas A, et al. Glucocorticoids induce an activated, antiinflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol. 2008;84(3):644-650.
24. Peranzoni E, Zilio S, Marigo I, et al. Myeloidderived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22(2): 238-244.
25. Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009;10(12):1252-1259.
26. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010;115(6):1247-1253.
27. Ugel S, Delpozzo F, Desantis G, et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol. 2009; 9(4):470-481.
28. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009; 69(4):1553-1560.
29. Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumorinduced myeloid-derived suppressor cells. J Immunol. 2009;182(9):5693-5701.
30. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010; 70(1):68-77.
31. Olsson B, Andersson PO, Jernås M, et al. T-cellmediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-1124.
32. Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet. 1997; 349(9064):1531-1536.
33. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008; 112(4):1325-1328.
34. Liu B, Zhao H, Poon MC, et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007; 78(2):139-143.
35. Li X, Zhong H, Bao W, et al. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood. 2012;120(16): 3318-3325.
36. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancerexpanded myeloid-derived suppressor cells induce anergy of NK cells through membranebound TGF-beta 1. J Immunol. 2009;182(1): 240-249.
37. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008; 205(10):2235-2249.
38. Nagaraj S, Youn JI, Weber H, et al. Antiinflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010;16(6):1812-1823.
39. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloidderived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007; 13(18 Pt 1):5243-5248.
40. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med. 2007;204(6):1463-1474.
41. Zoglmeier C, Bauer H, Nörenberg D, et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res. 2011;17(7):1765-1775.
42. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol. 2012;188(4): 1592-1599.
43. Guo C, Chu X, Shi Y, et al. Correction of Th1- dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol. 2007; 27(6):557-562.
44. Liu XG, Ma SH, Sun JZ, et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood. 2011;117(6): 2061-2069.
45. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloidderived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010;185(4):2273-2284.
46. Li S, Wang L, Zhao C, Li L, Peng J, Hou M. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol. 2007;139(4):605-611.
47. Ma L, Simpson E, Li J, et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood. 2015;126(2): 247-256.
48. Mouly E, Chemin K, Nguyen HV, et al. The Ets-1 transcription factor controls the development and function of natural regulatory T cells. J Exp Med. 2010;207(10):2113-2125.
49. Wang D, John SA, Clements JL, Percy DH, Barton KP, Garrett-Sinha LA. Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. Int Immunol. 2005;17(9):1179-1191.
50. Konno S, Iizuka M, Yukawa M, et al. Altered expression of angiogenic factors in the VEGFEts- 1 cascades in inflammatory bowel disease. J Gastroenterol. 2004;39(10):931-939.
51. Liu F, Fan H, Ren D, et al. TLR9-induced miR-155 and Ets-1 decrease expression of CD1d on B cells in SLE. Eur J Immunol. 2015;45(7): 1934-1945.
52. Nagaraj S, Nelson A, Youn JI, Cheng P, Quiceno D, Gabrilovich DI. Antigen-specific CD4(1) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res. 2012;72(4):928-938.
53. Kassel O, Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol. 2007;275(1-2):13-29.
54. Geng CD, Vedeckis WV. c-Myb and members of the c-Ets family of transcription factors act as molecular switches to mediate opposite steroid regulation of the human glucocorticoid receptor 1A promoter. J Biol Chem. 2005;280(52): 43264-43271.